Media Contact: Melody Udell
Our team would love to meet with you to demonstrate how MMIT, Panalgo, and our NorstellaLinQ data asset deliver end-to-end support from clinical trial planning to market access intelligence, powered by real-world evidence, AI-enabled analytics, and expert-level support.
Join 4,000+ managed care pharmacy professionals at AMCP 2026 in Nashville, TN, April 13-16. Explore cutting-edge education, earn CE credits, and dive into Al, real-world evidence, precision medicine and other emerging health care trends. Network with leaders from health plans, PBMs, pharma, and more.
Each year, Asembia’s Specialty Pharmacy Summit is at the epicenter of the pharmacy industry, providing a unique opportunity for stakeholders throughout the industry to understand challenges, generate solutions and define the future. Asembia’s AXS26 Summit will return to the Wynn & Encore Las Vegas April 26-30, 2026.
The Veeva Commercial Summit returns to Boston May 19-20, 2026. This invite-only event brings together top life sciences leaders that aim to help shape the future of customer engagement.
The ASCO Annual Meeting is more than a conference—it’s the place to be a part of something bigger. This is where groundbreaking science, innovation, and connection come together to shape the future of cancer care.
AMCP Nexus attracts more than 2,500 managed care decision-makers each fall. Attendees include individuals from health plans, PBMs, biopharmaceutical companies, consultants, and other leaders working within managed care pharmacy.
For this article on GLP-1 market dynamics, Investor’s Business Daily reached out to MMIT CCO Jayne Hornung for her insights on pricing, affordability, and whether the oral version of these drugs will reach a previously untapped market.
For this investigative article about the origins, operations and impact of alternative funding programs (AFPs), Fierce Healthcare asked MMIT to provide a custom survey of payers and PBMs. Most are concerned about the legality of AFPs, an opinion shared by manufacturers, many of which prohibit patients with an AFP from applying to their patient support programs.
PharmaVoice reached out to MMIT’s Alicia Heesen for insights into how Merck’s release of the subcutaneous agent Keytruda Qlex will extend its market share and increase potential revenue. Alicia shares payer preferences for faster, less expensive, and more convenient treatment options.
